-

Availability of Transgene’s Half-Year Financial Report as of June 30, 2023

STRASBOURG, France--(BUSINESS WIRE)--Regulatory News:

TRANSGENE (Paris: TNG) today announced that it has made available to the public and filed with the Autorité des marchés financiers its half-year financial report as of June 30, 2023.

The document is available on the Company’s website: www.transgene.fr, in the “Investors/Financial information” section.

This report comprises the following documents:

- 2023 half-year financial statements;
- Half-year management report;
- Statutory Auditors’ report on the 2023 half-year financial statements;
- Declaration by the person responsible for this half-year financial report.

Contacts

Transgene:
Lucie Larguier
Director Corporate Communications & IR
+33 (0)3 88 27 91 04
investorrelations@transgene.fr

Transgene

BOURSE:TNG

Release Versions

Contacts

Transgene:
Lucie Larguier
Director Corporate Communications & IR
+33 (0)3 88 27 91 04
investorrelations@transgene.fr

Social Media Profiles
More News From Transgene

Transgene Announces Upcoming Investor Meetings

STRASBOURG, France--(BUSINESS WIRE)--Regulatory News: TRANSGENE (Paris:TNG) today announces that Management will participate in several investor events in the upcoming investor events, as set out below. Transgene will meet institutional investors at the 13th Annual LifeSci Advisors Corporate Access Event in San Francisco from January 8 to 10, 2024, in conjunction with the J.P. Morgan Healthcare conference. The Company will also attend: 27th ODDO BHF Forum (virtual): January 15-16, 2024; Invest...

Transgene Strengthens its Leadership Team to Accelerate its Growth Strategy

STRASBOURG, France--(BUSINESS WIRE)--Regulatory News: Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, is pleased to announce the appointment of Arnaud Dubarry as Chief Financial Officer (CFO), effective January 1, 2024. Arnaud Dubarry will be based in Strasbourg and will be responsible for all aspects of the Company’s financial strategy, management and operations to accelerate the development of it...

Transgene Reports Business Update and Q3 2023 Financial Position

STRASBOURG, France--(BUSINESS WIRE)--Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces its business update and its financial position for the quarter ending September 30, 2023. During the third quarter of 2023, Transgene’s clinical-stage immunotherapy portfolio continued to advance. Notable progress included the treatment of the first patient in the Part B of Phase I trial assess...
Back to Newsroom